CL2015003554A1 - Preparado farmacéutico. - Google Patents
Preparado farmacéutico.Info
- Publication number
- CL2015003554A1 CL2015003554A1 CL2015003554A CL2015003554A CL2015003554A1 CL 2015003554 A1 CL2015003554 A1 CL 2015003554A1 CL 2015003554 A CL2015003554 A CL 2015003554A CL 2015003554 A CL2015003554 A CL 2015003554A CL 2015003554 A1 CL2015003554 A1 CL 2015003554A1
- Authority
- CL
- Chile
- Prior art keywords
- solution
- alfa
- radionucclid
- complex
- pharmaceutical preparation
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 229940102223 injectable solution Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Extraction Or Liquid Replacement (AREA)
- Saccharide Compounds (AREA)
Abstract
MÉTODO PARA GENERAR UNA SOLUCIÓN PURIFICADA DE POR LO MENOS UN RADIONÚCLIDO EMISOR ALFA, QUE COMPRENDE PONER EN CONTACTO UNA SOLUCIÓN QUE COMPRENDE DICHO AL MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA Y POR LO MENOS UN NÚCLIDO HIJO QUE TIENE POR LO MENOS UN LIGANTE SELECTIVO PARA DICHO POR LO MENOS UN NÚCLIDO HIJO Y SUBSIGUIENTEMENTE SEPARAR DICHA SOLUCIÓN DE POR LO MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA DE DICHO POR LO MENOS UN LIGANTE SELECTIVO; MÉTODO PARA REDUCIR LA RADIÓLISIS DE POR LO MENOS UN COMPONENTE ORGÁNICO EN UNA SOLUCIÓN; MÉTODO PARA LA ELIMINACIÓN DE POR LO MENOS UN RADIONÚCLIDO HIJO DE UNA SOLUCIÓN; CONJUNTO DE ELEMENTOS PARA LA FORMACIÓN DE UN PREPARADO FARMACÉUTICO DE POR LO MENOS UN COMPLEJO DE RADIOISÓTOPO EMISOR ALFA; DISPOSITIVO DE ADMINISTRACIÓN; Y MÉTODO PARA FORMAR UNA SOLUCIÓN INYECTABLE DE UN COMPLEJO CON EL ALFA-RADIONÚCLIDO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003554A1 true CL2015003554A1 (es) | 2016-07-15 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003554A CL2015003554A1 (es) | 2013-06-05 | 2015-12-04 | Preparado farmacéutico. |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715A1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| CN114902350A (zh) | 2019-12-05 | 2022-08-12 | 塞控斯公司 | 生产高纯度212Pb |
| WO2022157094A2 (en) | 2021-01-22 | 2022-07-28 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| JP5863640B2 (ja) * | 2009-04-29 | 2016-02-16 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 免疫複合体の精製 |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko not_active Expired - Fee Related
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en not_active Ceased
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh not_active Expired - Fee Related
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 HR HRP20200456TT patent/HRP20200456T1/hr unknown
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en not_active Ceased
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009876A (es) | Encapsulamiento y desencapsulamiento de medios. | |
| MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
| MX2017016676A (es) | Composicion envasada. | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| CY1116579T1 (el) | Φαρμακευτικες μορφες δοσολογιας ελεγχομενης απελευθερωσης | |
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
| AR096183A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco | |
| BR112015032445A2 (pt) | componente semicondutor orgânico | |
| BR112015025302A2 (pt) | embalagem para alojar pelo menos um artigo, matriz para formar uma embalagem para alojar pelo menos um artigo, embalagem para alojar pelo menos um artigo, matriz para formar uma embalagem, e método para formar uma embalagem | |
| BR112017000022A2 (pt) | nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas | |
| CY1120481T1 (el) | Kv1.3 ανταγωνιστες και μεθοδοι χρησης | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| MX2018002164A (es) | Anticerpo anti-epha4. | |
| CL2016001265A1 (es) | Método y sistema para diseñar aviones. | |
| BR112016005207A8 (pt) | métodos e sistema para tratamento de uma formação subterrânea | |
| MX2015015906A (es) | Mejoras en o con relacion a compuestos organicos. | |
| BR112018000464A2 (pt) | sistema de armazenamento gasoso, métodos para produzir e utilizá-lo | |
| AR097210A1 (es) | Composición para la aglomeración de finos | |
| MX2020003665A (es) | Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. | |
| BR112014029264A2 (pt) | microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo | |
| MX2015016628A (es) | Metodo para tratar infeccion intracelular. | |
| DOP2015000294A (es) | Preparado farmacéutico |